Tr1 cells for use in atherosclerosis

Details Tr1 cells for use in atherosclerosis Tr1 cells for use in atherosclerosis

2011-07-26

2011-07-26

Skelding, Zachary (Department: 1644)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C424S093210

Reexamination Certificate

active

07985409

ABSTRACT:
The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.

REFERENCES:
patent: 7771932 (2010-08-01), Groux et al.
patent: 2002/0034500 (2002-03-01), Levings et al.
patent: 2004/0191235 (2004-09-01), Groux et al.
patent: WO 02/092793 (2002-11-01), None
patent: WO 2005000344 (2005-01-01), None
Groux #2 et al., Transplantation. May 15, 2003;75(9 Suppl):8S-12S.
Mallat, Z., et al., “Induction of a Regulatory T Cell Type 1 Response Reduces the Development of Atherosclerosis in Apolipoprotein E-Knockout Mice,”Circulation, 2003, pp. 1232-1237, vol. 108(10).
Groux, H., et al., “A CD4+ T-Cell Subset Inhibits Antigen-Specific T-Cell Responses and Prevents Colitis,”Nature, 1997, pp. 737-742, vol. 389(6652), MacMillan Journals, Ltd., London, United Kingdom.
Wakkach, A., et al., “Characterization of Dendritic Cells that Induce Tolerance and T Regulatory 1 Cell Differentiation In Vivo,”Immunity, 2003, pp. 605-617, vol. 18(5), Cell Press, USA.
McGuirk, P., et al., “Pathogen-Specific T Regulatory 1 Cells Induced in the Respiratory Tract by a Bacterial Molecule that Stimulates Interleukin 10 Production by Dendritic Cells: A Novel Strategy for Evasion of Protective T Helper Type 1 Responses byBordetella pertussis,” Journal of Experimental Medicine, 2002, pp. 221-231, vol. 195(2), Tokyo, Japan.
International Search Report for PCT/IB2004/002858 completed Nov. 2, 2004.
Barrat, F., et al., “In Vitro Generation of Interleukin 10-Producting Regulatory CD4+ T Cells is Induced by Immunosuppressive Drugs and Inhibited by T Helper-Type 1 (Th1) and Th2-Inducing Cytokines”,J. Exp. Med., Mar. 4, 2002, vol. 195, No. 5, pp. 603-616.
Binder, C., et al., “Pneumococcal Vaccination Decreases Atherosclerotic Lesion Formation: Molecular Mimicry BetweenStreptococcus pneumoniaeand Oxidized LDL”,Nature Medicine, Jun. 2003, vol. 9, No. 6, pp. 736-743.
Cavani, A., et al., “Human CD4+ T Lymphocytes with Remarkable Regulatory Functions on Dendritic Cells and Nickel-Specific Th1 Immune Responses”,The Journal of Investigative Dermatology, 2000, vol. 114, pp. 295-302.
Chen, Y., et al., “Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis”,Science, Aug. 1994, vol. 265, pp. 1237-1240.
Cottrez, F., et al., “T Regulatory Cells 1 Inhibit a Th2-Specific Response In Vivo”,The Journal of Immunology, 2000, vol. 165, pp. 4848-4853.
Daugherty, A., et al., “T Lymphocytes in Atheroscleropsis: The Yin-Yang of Th1 and Th2 Influence on Lesion Formation”,Circulation Research, 2002, vol. 90, pp. 1039-1040.
Doetze, A., et al., “Antigen-Specific Cellular Hyporesponsiveness in a Chronic Human Helminth Infection is Mediated by Th3/Tr1-Type Cytokines IL-10 and Transforming Growth Factor-β but not by a Th1 to Th2 Shift”,International Immunology, 2000, vol. 12, No. 5, pp. 623-630.
Fukaura, H., et al., “Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Factor-b1-Secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients”,J. Clin. Invest., Jul. 1996, vol. 98, No. 1, pp. 70-77.
Glass, C., et al., “Atherosclerosis: The Road Ahead”,Cell, Feb. 2001, vol. 104, pp. 503-516.
Groux, H., “An Overview of Regulatory T Cells”,Microbes Infect., 2001, vol. 3, pp. 883-889.
Gupta, S., et al., “IFN-γ Potentiates Atherosclerosis in ApoE Knock-Out Mice”,J. Clin. Invest., Jun. 1997, vol. 99, No. 11, pp. 2752-2761.
Hansen, P., et al., “Freunds Adjuvant Alone is Antiatherogenic in apoE-deficient Mice and Specific Immunization Against TNFα Confers no Additional Benefit”,Atherosclerosis, 2001, vol. 158, pp. 87-94.
Hansson, G., “Immune Mechanisms in Atherosclerosis”,Arterioscler. Thromb. Vasc. Biol., 2001, vol. 21, pp. 1876-1890.
Laurat, E., et al., “In Vivo Downregulation of T Helper Cell 1 Immune Responses Reduces Atherogenesis in Apolipoprotein E-Knockout Mice”,Circulation, 2001, vol. 104, pp. 197-202.
Lee, T-S., et al., “The Role of Interleukin 12 in the Development of Atherosclerosis in ApoE-Deficient Mice”,Arterioscler. Thromb. Vasc. Biol., 1999, vol. 19, pp. 734-742.
Levings, M.K., et al., “IFN-a and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells”,The Journal of Immunology, 2001, vol. 166, pp. 5530-5539.
Liuzzo, G., et al., “Molecular Fingerprint of Interferon-y Signaling in Unstable Angina”,Circulation, Mar. 2001, vol. 103, pp. 1509-1514.
Liuzzo, G., et al., “Monoclonal T-Cell Proliferation and Plaque Instability in Acute Coronary Syndromes”,Circulation, 2000, vol. 101, pp. 2883-2888.
Liuzzo, G., et al., “Perturbation of the T-Cell Repertoire in Patients with Unstable Angina”,Circulation, Nov. 1999, vol. 100, pp. 2135-2139.
Lusis, A., “Atherosclerosis”,Nature, Sep. 2000, vol. 407, pp. 233-241.
MacDonald, A.J., et al., “CD4 T Helper Type 1 and Regulatory T Cells Induced Against the Same Epitopes on the Core Protein in Hepatitis C Virus—Infected Persons”,The Journal of Infectious Diseases, 2002, vol. 185, pp. 720-727.
Mallat, Z., et al., “Increased Plasma Concentrations of Interleukin-18 in Acute Coronary Syndromes”,Heart, 2002, vol. 88, pp. 467-469.
Mallat, Z., et al., “Protective Role of Interleukin-10 in Atherosclerosis”,Circ. Res., 1999, vol. 85, pp. 17-24.
Mallat, Z., et at, “Interleukin-18/Interleukin-18 Binding Protein Signaling Modulates Atherosclerotic Lesion Development and Stability”,Circ. Res., 2001, vol. 89, pp. 41-45.
McGuirk, P. et al., “Pathogen-Specific Regulatory T Cells Provoke a Shift in the Th1/Th2 Paradigm in Immunity to Infectious Diseases”,Trends in Immunology, Sep. 2002, vol. 23, No. 9, pp. 450-455.
Oslund, L.J., et al., “Interleukin-10 Blocks Atherosclerotic Events In Vitro and In Vivo”,Arterioscler. Thromb. Vasc. Biol., 1999, vol. 19, pp. 2847-2853.
Pinderski, L.J., et al., “Overexpression of Interleukin-10 by Activated T Lymphocytes Inhibits Atherosclerosis in LDL Receptor-Deficient Mice by Altering Lymphocyte and Macrophage Phenotypes”,Circ. Res., 2002, vol. 90, pp. 1064-1071.
Roncarolo, M.G., et al., “Type 1 Regulatory Cells”,Immunological Reviews, 2001, vol. 182, pp. 68-79.
Shevach, E.M., “Regulatory T Cells in Autoimmunity”,Annu. Rev. Immunol., 2000, vol. 18, pp. 423-449.
Von Der Thusen, J.H., et al., “Attenuation of Atherogenesis by Systemic and Local Adenovirus-Mediated Gene Transfer of Interleukin-10 in LDLr-/-Mice”,The FASEB Journal, Dec. 2001, vol. 15, pp. 2730-2732.
Whitman, S.C., et al., “Interleukin-18 Enhances Atherosclerosis in Apolipoprotein E-/-Mice Through Release of Interferon-γ”,Circulation Research, 2002, vol. 90, pp. e34-e38.
Whitman, S.C., et al., “Exogenous Interferon-γ Enhances Atherosclerosis in Apolipoprotein E-/-Mice”,American Journal of Pathology, Dec. 2000, vol. 157, No. 6, pp. 1819-1824.
Zhou, X., et al., “Transfer of CD4+ T Cells Aggravates Atherosclerosis in Immunodeficient Apolipoprotein E Knockout Mice”,Circulation, 2000, vol. 102, pp. 2919-2922.

Affiliated with

Also associated with

Rating

Tr1 cells for use in atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tr1 cells for use in atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tr1 cells for use in atherosclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2639999